EL.En. S.p.A. (ELN) Earnings Call Transcript & Summary

September 11, 2025

Borsa Italiana IT Health Care Health Care Equipment and Supplies earnings 74 min

Earnings Call Speaker Segments

Bianca Fersini-Mastelloni

executive
#1

Nicola.

Nicola Fiore

unknown
#2

Good afternoon, everyone, and welcome to the conference call on EL.En.'s AFIE 2025 financial results. This call is being recorded today, and at the end there will be a chance to ask questions. Joining me are Andrea Cangioli, EL.En.'s CEO, and Enrico Romagnoli, who serves as EL.En.'s Chief Financial Officer and Investor Relations Manager. Before we start, please be aware that during this conference call, management will make remarks about future expectations, plans, prospects, and forward-looking statements. Some statements on this call — among them those dealing with the company's beliefs, plans, objectives, estimates, or expectations regarding possible future results or events — are forward-looking statements. Forward-looking statements carry known or unknown risks, including general economic and business conditions in the industry where we operate. Should our assumptions prove inaccurate, these statements will be affected. As a result, no forward-looking statement can be guaranteed, and actual future results, performance, or achievements could differ materially from those expressed or implied by such forward-looking statements. The company assumes no obligation to update the contents of the forward-looking statements to reflect events or circumstances that may arise after the date of year-of. At the end of the presentation, if you need to ask a question, please book your question on the chat of Bianca Fersini Mastelloni or raise your virtual hand.

Nicola Fiore

unknown
#3

I'll take questions in the order they come in. Right now, I'd like to hand things over to Andrea Cangioli. Andrea, the floor is yours.

Andrea Cangioli

executive
#4

Good morning. Thank you, Nicola, and thanks as well to Bianca for the introductions on this call. I appreciate everyone joining us following the release of our financial report as of June 30, 2025. Enrico Romagnoli is here with me today, and I want to thank him for handling the details of our financial reporting, which he'll walk you through shortly. The figures have been available since last night, so you've already seen that our performance across the six months was solid on revenue generation. On a consolidated basis, revenues came in above €285 million, an increase of more than 5% versus the same period in 2024, in line with our guidance and confirming the positive momentum from the first quarter. At EBIT level, the objective of surpassing 2024's result was not achieved. The EBIT figure was actually quite robust, at €34.6 million, representing a 12.1% EBIT margin, yet it fell short of the €37.2 million posted in the corresponding semester of 2024. The medical sector turned in an excellent performance, slightly beating the initial expectation given overall conditions in the economic environment. Revenue growth in the industrial sector came in below expectations, and its reduced contribution to consolidated EBIT accounts in full for the shortfall in 2024/05 consolidated EBIT versus last year.

Andrea Cangioli

executive
#5

When I talk about the broader economic picture, what I mean is a general atmosphere of uncertainty in international affairs. That comes mainly from international diplomacy's failure to put an end to the wars in Ukraine and Palestine, and from the trade war started by the U.S. administration, which is reshaping trade relations as well as political relations among the world's most powerful countries, Europe included. The wars have been going on for so long now that, despite the danger of further escalation, the markets behave as though they have grown used to this situation. The trade war, as things stand, is hitting our business: it makes selling our products in the U.S. more expensive, it makes them less profitable because of a weaker U.S. dollar, and it also holds back interest rate cuts in the U.S. because of the inflation that tariffs are expected to drive. We have explained previously how interest rates and expectations regarding changes in interest rates affect our capital goods market, where customers mostly finance their investments through debt and are therefore assisted in their investment decisions by lower interest rates. Naturally, conditions in our specific markets are shaped by this general situation, and the business trend shown by the financial results that are available for certain of our competitors confirms it.

Andrea Cangioli

executive
#6

Now, looking below the EBIT line — and again, I'm referring to the consolidated financial results of the EL.En. group — every item below EBIT played a part in making the difference between the 2024 results and the 2025 results larger. Currency exchange fluctuations weighed on financial income to the tune of about €3.5 million. The Chinese operations, which are on the point of being divested and sold, contributed a loss of €4 million in 2025, a worse outcome than the €3.2 million loss contribution recorded as of June 2024. Then in 2024 we had a €5 million extraordinary income, booked as a remeasurement of a financial debt that was no longer outstanding at that time — an item that, naturally, could not be repeated in 2025. What the very bottom line shows — a wide gap between the €27.3 million income of 2024 and the €17.9 million income of 2025 — does not adequately depict or reflect how we are currently performing. Instead of focusing on this gap, which is mostly produced by events beyond our control or by a business area that is no longer part of the group at the Chinese facilities, we should now focus on the remarkable achievements we delivered this year. First of all, revenue and EBIT grew in the medical sector.

Andrea Cangioli

executive
#7

Each of those rose over 5%, and these figures represent the sum of a number of more targeted wins and accomplishments. Following the late-2024 launch of the Magneto urology laser system, Quanta System's leadership position in laser devices for urology applications was confirmed and reinforced. Nearly 900 urology systems were delivered during the first six months of 2025 — among them TFL lasers too, by which I mean TFL or systems built on other fiber laser sources, and those encompass not just solid-state lasers such as the Magneto — surpassing €35 million in revenues. With the installed base growing and manufacturing capacity at our Samarate plant also climbing steadily, revenue from sales of sterile optical fibers — the consumable required for every single surgical procedure — rose substantially, topping €20 million across the six months, with close to 180,000 fibers delivered. Since demand in hair removal, our primary aesthetic application segment, has been softening gradually over recent years, we focused our efforts, on one hand, on enhancing the performance and effectiveness of our laser hair removal systems so as to counter the market slowdown. On the other hand, we focused on enhancing the performance and effectiveness of our systems and technology dedicated to anti-aging procedures, and on giving them adequate marketing support.

Andrea Cangioli

executive
#8

I'm referring to technologies that enhance how the skin looks, eliminating finer lines, triggering collagen renewal, giving the skin radiance and suppleness, that firm the skin, offering solutions for looseness, that take away excess from the face and the décolleté. I'm referring to Red Touch Pro and Onda Pro by EL.En., to Discovery Pico by Quanta System and Toro by EL.En., and to the CO2 laser product range, which includes Theta Pro by EL.En. and Duo Laser by Quanta System. As I mentioned, revenues coming from these application areas rose sharply in 2025, compensating for weaker demand in other disciplines. Although the overall result in the industrial sector was neither successful nor satisfying, particularly because of soft demand in the manufacturing markets in Italy, we can point to several activities that during these six months laid the groundwork for a notable strengthening of our companies' ability to compete. The Chinese business, which was no longer adding to the group's performance, has been divested and no longer represents a burden on management and financial resources. The network of European subsidiaries launched by LASIK in the marketing field over the last two years is stabilizing and turning into an increasingly dependable source of revenue, also adding to profit, at least for the older subsidiaries.

Andrea Cangioli

executive
#9

Kataj Penta is now following a comparable approach, having quickly established three subsidiaries across Poland, Germany, and Spain, and at present these are clearly a burden on expenses and on EBIT, though we expect them to start contributing to profit generation before long. Kataj took control of Nexam, a modest firm located here in the Florence area that focuses on building automation systems which are strictly complementary to Kataj's high-power laser-shaped metal cutting systems. Installed together with a laser system, Nexam's automation systems raised the laser system's overall performance and productivity, giving Kataj a way to differentiate itself in its highly competitive market by boosting system performance and offering broader customization capability. Kataj is chasing a competitive advantage in two ways: on one hand by expanding its offering and integrating automation systems into it, and on the other by raising its level of service and its proximity to the end user via the organization of local sales and service facilities. One more thing I want to note: if you examine our financial performance, among the weakest results in financial terms during the six months was the industrial division of EL.En., the group's mother company.

Andrea Cangioli

executive
#10

Our efforts on the mid-power CO2 laser sources designed for specialized manufacturing uses, along with work on how the scanning units built around our proprietary galvanometers perform, look likely to lay the groundwork for revenues to rebound down the road. In that connection, I want to note that our 1.5 kilowatt RF excited CO2 laser source is now achieving a degree of stability such that we are actively working toward, and anticipate, bringing out a 2 kilowatt laser source in a reasonable timeframe. That step will raise the top power level in our lineup, crossing a threshold that might unlock a number of attractive application markets. One more point I'd like to address in my comments concerns cash generation. During the period, the net financial position balance fell by €20 million. I don't regard this movement as any kind of particular issue, since the seasonality of the networking capital balance always works against a group during the first six months. We paid out dividends amounting to €18 million and change, and recorded investments of €15 million, of which €6 million I would characterize as mid-term liquidity investments. Without question, the net financial position ranks among the group's historical strengths.

Andrea Cangioli

executive
#11

It's among the elements making up the group's wealth. The remaining elements are far less tangible and reside in this organization's ability to keep evolving and innovating its high-quality product range, confirming its recognized standing among the world's leading players, also via several solid commercial relationships built over the years. Because its offering is unique and differentiated, the group can sustain a high customer perception of its value, which may be described as an excellent market positioning. Notwithstanding the macroeconomic uncertainties of recent months, the offerings of our business units stay attractive to customers owing to effective product development, marketing support, training, and the excellent technical assistance that accompanies after-sales service in all markets. One last thing before I hand the microphone to Enrico, a comment on the U.S. tariffs. The 50% tariff our products are called to pay when entering the U.S. constitutes today a cost increase in the chain that delivers our product to our end users in the U.S. The tariff-induced cost increase could either be absorbed in full by our distributors, which could accept the minor reduction on margins that the cost increase would represent, given the high resale margin that they often apply, or could, if reverted to end users, be considered marginal price increases and do not affect demand, maintaining the price in a range where demand is, let's say, unelastic to price.

Andrea Cangioli

executive
#12

A cost reversal of that kind, passed on to end users, might drive prices into a zone where demand would fall off because of price elasticity. Those represent every one of the theoretical scenarios. In both our industrial distribution and our medical distribution, the innovative content and the quality perception of the product have always been a key element for selling in the U.S., and that is what lets us sell at premium prices and margins — meaning we keep the product's market positioning in an area where tariff costs do not materially affect margins and volumes for our distributors. This directly links our ability to effectively sell in the U.S. market to our innovation capabilities. It is hard today to predict the mid-term market adjustments the new tariffs will bring about. As of today, our American customers have reacted positively, and demand fluctuation has been limited and tied more to specific acceptance of individual products than to the extra tariff cost. On this point, we have to note that the implicit tariff that the weakening of the U.S. dollar is in any case imposing on our sales to the U.S. will be more effective in the second half of 2025, when the average foreign exchange rate will be steadily above $1.15 for one euro, and the presence of the extra tariff cost on our distributors will make it difficult to neutralize the forex penalization on our margins, as we have done in other circumstances.

Andrea Cangioli

executive
#13

Enrico, please go ahead with whatever you'd like to say about the financial report.

Enrico Romagnoli

executive
#14

Thanks, Andrea, and good morning, everyone. Turning to the year-end, we prepared the half-yearly report under IFRS accounting standards, leaving out the line-by-line consolidation of the Chinese activities for both 2025 and 2024, because of the ongoing talks to sell that division in line with IFRS 5. The majority stake in the Chinese companies was sold on July 15. During the first half of 2025, the EL.En. group posted consolidated revenues of €285 million, a rise of 5.1% from the €271 million recorded in June 2024. The medical sector grew by more than 5%, and the industrial sector by more than 3%. Gross margin came to €106 million, up 5% versus the €120 million of June 2024, representing 44% of revenue, consistent with last year. Note that in 2024 the group booked proceeds from insurance and government reimbursement tied to flood damage from November 2023 amounting to €1.9 million, or 0.7% of revenues, whereas in 2025 Asklepion recognized €1.3 million in R&D grants, equal to 0.4% of revenue. Apart from those two items, there was no recurring income affecting gross margin on sales. Had they been excluded, gross margin in 2025 would have been 0.4% better, thanks to an improved sales mix.

Enrico Romagnoli

executive
#15

Operating expenses went up, both in absolute terms and in how much they weighed on sales, driven mainly by G&A, R&D, and IT costs, along with sales and marketing activities. Staff costs also rose. That increase in staff costs stems from more headcount and higher salaries. EBITDA came in positive at €42.2 million, a decline of 2.7% versus the €43.3 million recorded on June 2024. The EBITDA margin for 2025 stood at 14.8%, compared with 16% in 2024. Depreciation, amortization and provision totaled €7.0 million in 2025, against €6.1 million in 2024. The increase was primarily due to the reversal of the provision for risk and charges in 2024 for €1.6 million, reflecting certain legal disputes that were resolved more favorably than expected. Net of that amount, the overall cost aggregate is in line with the previous year. EBIT for the six months was €34.7 million, down 7% from €37.3 million in 2024. The margin on revenue was 12.1%, lower than the 13.7% of last year. As Andrea already mentioned, financial management recorded a loss of €2.6 million. Specifically, in the first six months, interest income generated by liquidity was €1.7 million, while interest expenses on debt were €0.9 million.

Enrico Romagnoli

executive
#16

Exchange rate differences produced a sharply negative balance of €2.5 million, and on top of that, a one-time exchange rate loss of roughly €1 million was recorded in Q1, following the release of the currency conversion reserve tied to the sale of the majority stake in WIDAS. Within other income, the prior year included a one-time gain of €5 million from remeasuring the liabilities connected to the earnout payable to former minority Chinese shareholders should Pentalas list on Zhejiang. Pre-tax income came in at a positive €31.7 million, below the €42.3 million posted on June 2024. This continued operation captures the net contribution to the consolidated result from the Chinese activities under this proposal. The negative impact was €4 million versus €3 million a year earlier. What mainly drives the negative impact in 2025 is the devaluation of the KBF equity investment during the first six months of 2025. The effective tax rate rose to 32% in 2025 from 27% last year, and the chief reason for that rise is the non-taxability of the €5 million booked in other income last year. Turning to the balance sheet figures, we observe growth in total non-current assets and networking capital while the net financial position declined.

Enrico Romagnoli

executive
#17

The ratio of networking capital to sales is roughly in line with last year's figure. To break it down, cash flow during the period reflected a decrease of about €20.6 million in the group's net financial position, moving from €110.6 million at the close of 2024 to €90 million at the end of June 2025. That decrease also reflected dividends distributed by the group totaling €18.6 million, capital expenditure of €10 million on fixed assets, €6 million put into mid-long-term liquidity investments, €2 million invested in ownership shares, and the seasonal expensive pattern of the networking capital components, which produced a cash absorption of roughly €20 million across the six months. Turning to the sales analysis, within the medical sector, system sales posted strong growth across all major segments. In the aesthetic segment, up 3%, the highly favorable trend for anti-aging applications carried on. Within surgical applications, up 14%, urology systems went on delivering significant sales growth. The performance in physiotherapy, up 7%, was very satisfactory as well, helped by significant incremental innovation in the range of products offered, broader and more effective coverage of international markets, and the relaunch of sales in Italy. Sales of consumables and after-sales services stayed very satisfactory, powered by sales of optical fibers for surgical applications, which held service revenue growth at 6%, notwithstanding the low service contract revenue from the Japanese companies with us, whose majority stake was sold in February 2025.

Enrico Romagnoli

executive
#18

Looking at the industrial side, the cutting segment — which excludes the Chinese companies now — kept growing at more than 6%, helped by the strong sales performance of the Brazilian subsidiaries, which added $6 million of revenue during the first six months, along with the inorganic contribution from Nexam of $1 million. Nexam is a business focused on building automation systems for Kataj Penta laser systems, and a majority stake in it was bought at the start of 2025. LASIK likewise did well in the marketing segment, with its subsidiaries carrying more weight, whereas things were tougher for Othalas, and the industrial area of EL.En. stood out because of lower revenue coming from sources serving industrial applications. Revenue from after-sales service held steady. Turning to the split by area, growth in Italy was driven earlier on by the medical sector, while on the industrial side, even though order intake was strong — a good sign for the remainder of the year — total revenue fell short of the already weak results recorded in the first half of 2024. Across European markets, the growth came thanks to industrial companies, which are steadily constructing their own direct distribution network. LASIK has branches, several of them nearly fully up and running, in Poland, the UK, Germany, Spain, and France. Starting in 2025, Kataj too has just opened branches in Spain, Germany, and Poland.

Enrico Romagnoli

executive
#19

In Europe, our medical segment saw sales rise by 13%. Outside Europe, revenue dipped a bit in both sectors: industrial was hurt by softer demand from US markets, while medical was weighed down by weak results in the Middle East. Andrea, over to you on the 2025 guidance. Andrea, your microphone.

Andrea Cangioli

executive
#20

I'm here now—sorry, my microphone was switched off while I was speaking. With a few remarks on guidance, I'll bring this portion of the prepared remarks to a close. To the very clear statement we issued in the press release, I'd like to add just a small bit of color. Given the delay we're facing after six months, and taking into account certain unfavorable circumstances I discussed earlier on this call, reaching the goal of surpassing 2024's EBIT has become more difficult. A substantial backlog of orders is there for us to draw on, and, as always, so are our capabilities.

Nicola Fiore

unknown
#21

So, keeping to the framework I laid out in my remarks, we confirmed the target for annual revenue growth versus 2024. Assuming nothing external gets in the way of additional order intake over the next few months — which we need in order to hit the yearly targets — EL.En. is aiming to improve its EBIT as well in the 2025 financial year. That brings us to the end of the prepared portion of this presentation, and we're ready to take your questions.

Bianca Fersini-Mastelloni

executive
#22

Alright, we're opening the Q&A portion now, and there are two analysts on our list. I'll hand things over to Giovanni Selvetti of Berenberg. Please go ahead, Giovanni.

Giovanni Selvetti

analyst
#23

Hi, everybody. Is my audio coming through okay?

Nicola Fiore

unknown
#24

Yes, good morning out there. Hi there, Giovanni.

Enrico Romagnoli

executive
#25

Alright.

Nicola Fiore

unknown
#26

Hello there, Giovanni.

Giovanni Selvetti

analyst
#27

Good afternoon, everyone, and thank you for the question. My first one concerns the medical division, which is expanding at a healthy pace. Looking only at the sequential movements in Q2, there's a pronounced rise in surgical applications, yet aesthetics is down versus a year ago. I'd like to know what's behind that. And when I read your remark in the Asklepion press release, it appears that this is the sole business in the group that isn't delivering. From what I recall, it has been troublesome for the last two or three years, first with procuring materials and second, at this point, with sales. So what's the story there? On your closing remark about guidance, you said that with the order backlog in view, you feel confident about hitting the guidance. Is that mainly medical, or is it an improvement in industrial that you're seeing, which, from what you said at the start, seems to be the main driver of the gap in each one? It's a mix of both. Could you give a little more color on the order backlog. The third one is probably about staff cost.

Giovanni Selvetti

analyst
#28

It seems clear to me that personnel costs are climbing pretty sharply compared with a year ago. The real question is what is behind that. Enrico mentioned it comes from both higher salaries and a larger headcount. Is it mostly tied to bringing on salespeople for the new subsidiaries, which, of course, are now fixed costs with no revenues attached? Or are there other dynamics we ought to know about?

Andrea Cangioli

executive
#29

Alright, I'll take your questions in order. Yes, that's correct. I mean, it is documented. Revenue from laser systems used for aesthetic purposes showed a slight drop during the first six months. As I also pointed out in my remarks, that's primarily because demand weakened in our biggest application segment, namely hair removal, which was and remains the case. When we examine how hair removal performed on its own, it is going down. We made up for the bulk of the hair removal decrease through gains in these other applications. This situation pleases us also since we can hold out hope that a rebound in hair removal may occur or could occur. We're putting in effort toward that too. We're additionally building an increasingly stronger position in those applications apart from hair removal, where the market is expanding and is anticipated to expand. That's the overall picture. Regarding Asklepion, two factors, in my view, are currently affecting Asklepion's capacity to perform effectively while competing in the medical aesthetic markets. The first is that we underwent a restructuring of our R&D capabilities, which isn't simple at present in Germany, since although we're located in a city with full employment such as Vienna, where we lack the ability to readily obtain a certain caliber of employees, or we can do so by driving up costs.

Andrea Cangioli

executive
#30

That partly addresses your question about staff cost as well. When you look at the rise in medical staff cost, some of it comes from Asklepion, where we saw a meaningful cost increase driven by the need to keep people from leaving. We have to raise the average salary, or the total salary cost. The second reason Asklepion is struggling somewhat is that, among the group's companies, it is the one most dependent on hair removal. Historically it has also had products for anti-aging and other applications, but its flagship product, the Remedial Star, is a hair removal laser system. It is tightly linked to the hair removal market. Naturally, we are investing to differentiate. We have a new product for hair treatment — hair, not hair removal, for hair treatment, hair, the hair that stays on the hand — which is very promising in the cosmetic field. Right now we are struggling a bit, fighting this rather unfavorable moment in hair removal. Again, I now move to question number three, which is staff cost, because you gave me the chance to jump on it while talking about Asklepion.

Andrea Cangioli

executive
#31

Asklepion is among the factors pushing staff costs up. What I need to point out is that the rise in staff cost, particularly when you set it against revenues, shows up mostly in industrial, where we're bringing on all those people through the subsidiaries, and where we're also taking on people for R&D. There, as I mentioned, revenue went up, but we had been looking for a steeper revenue increase, so the cost of staff weighs more heavily on revenue. Naturally, when you list the reasons behind the higher staff cost, there are a number of causes. One is the answer to inflation, which arrives through contractual agreements raising salaries. Another stems from the necessity of continuing to draw people in by paying salaries above the average, and by providing benefits, bonuses, and salary increases. The third is simply that headcount is expanding in certain activities. Naturally, we become somewhat more rigid to revenue fluctuation, but if we don't bring those people on board and if we don't grow the number of employees for a set of activities that aren't necessarily located in production capabilities but more in support capabilities as well, such as in regulatory, in R&D, we won't be able to see revenues growing.

Andrea Cangioli

executive
#32

That answers the staff cost question. Now, coming back to your second question, Giovanni, about the backlog: yes, we're happy with the backlog overall, in both medical and industrial. It's stronger than in other recent periods we've been through, in medical as well as industrial. You should know that, as we've always told you, typically only a very small portion of our backlog — of our order books — is secured. So we have orders to deliver, but at the moment the customer has to confirm their willingness to pay for the delivery. The order books are a very good leading indicator of the health of our market. As I said in the press release and also in my remarks, of course, we need this tension in demand — I mean this positive tension in demand — to be sustained over the period so we have confirmation that the entire order backlog converts into sales, and converts into sales by the end of the year, so it contributes to revenues that would raise yearly revenues and, through leverage effect, would improve EBIT relative to the first six months and also relative to the previous year.

Giovanni Selvetti

analyst
#33

Sure, let me ask one more about hair removal, then I'll rejoin the queue, and afterward, if time permits, I'll pose a few more questions. Regarding hair removal, you mentioned that part of the issue is Asklepion underperforming, which leans toward hair removal. Is part of it also because Signature's sales might be slipping due to the new, shall we say?

Andrea Cangioli

executive
#34

Yeah, I held back on bringing it up since it could sound like I was making excuses. That's not what I'm doing—I'm just explaining what's happening. You're right, Giovanni. A portion of the drop in hair removal stems from the fact that Signature, a new property with new management, is essentially phasing out the Elite IQ product line, since they'll be sourcing a comparable product from their Korean partner, Lutronic. You're right, part of the hair removal decline comes from the missing Signature relationship. That matters because it likely accounts for over half of the revenue decrease in hair removal across the six months, though it doesn't explain the entire decline, so the overall trend is still there regardless.

Giovanni Selvetti

analyst
#35

All right, I’ll rejoin the queue, and Bianca, if there’s enough time left at the end, I’ll simply ask a few more.

Bianca Fersini-Mastelloni

executive
#36

Moving on, we have another question, and this one is from Carlo Maritano. Carlo, please go ahead.

Carlo Maritano

analyst
#37

Good afternoon, Andrea and Enrico. I have three questions. First, back to the industrial sector. Looking at the geographic breakdown, Italy stands out as the main factor, just as you mentioned earlier. Given that last year was already weak, I'd like to know what the reason is. Is it still Industry 5.0 that's struggling, or do you think some other factor explains this weakness? Second, on the medical business. In the geographic breakdown, I see that the rest of the world was a little bit weak in the second quarter. Is that tied to the consolidation of WIDAS, or are certain geographic areas struggling? Third, I know Laser Sources is quite a small business for you, but I see they are struggling in this period. What's happening in that division, and do you think it will improve going forward? Thank you.

Andrea Cangioli

executive
#38

Thanks for asking that. It lets me go into a bit more detail on something I didn't want to spend too long on during my presentation. Yes, the industrial market — manufacturing in Italy — hasn't rebounded very strongly. Order books are building positively, but we've been struggling quite a bit in cutting as well as in laser marking, in both cases. We're now counting on a recovery, because you're right, we're up against a weak year and it's weak again, and we were really counting on a rebound. That's when I say we expect a stronger rebound. I'm mainly talking about the Italian industrial market. The second question is the rest of the world in medical. What happened in the second quarter? I was trying to look into the numbers and see whether with us — of course, with us accounts for part of the decline, because we no longer have with us revenues. I wouldn't say.

Carlo Maritano

analyst
#39

Regarding our 2020 and 2024 goals, Andrea Cangioli will now take you through them.

Andrea Cangioli

executive
#40

See?

Carlo Maritano

analyst
#41

Am I coming through okay? For 2024, WIDAS brought in $5.6 million in revenues, whereas 2025 shows $1.4 million, since we consolidated only through February. That gap comes to $4 million — $4.2 million.

Andrea Cangioli

executive
#42

Yes, we had that variance, and then there was Signature, which Giovanni Salveti brought up. To provide a bit more detail, we delivered an excellent performance in the Far East. What I mean is, we did very well there, but it was much weaker in the United States. Naturally, Japan isn't with us, though Japan is coming along nicely in the other medical applications following a low point in 2024. The third question — you had another question as well, Carlo.

Carlo Maritano

analyst
#43

Laser, and laser sources.

Andrea Cangioli

executive
#44

Yes, laser sources. Yes, yes, yes. We went through a really tough transition period, since a big portion of our lasers are tied to textiles. As you know, we sell laser sources used for laser stonewashing of denim. The entire clothing market has been struggling, from luxury brands all the way to the more standard brands. This kind of stagnation in the textile and clothing market is hitting us. We had interesting cooperations in two other segments, one of which we still feel is very valuable, namely digital converting. That means packaging, automation in the packaging industry. We had a very important cooperation that hopefully has now bottomed out again with an Israeli company. It is a listed company that, quite unexpectedly, filed for bankruptcy in the first quarter. Not only did we lose the revenues we expected, but we also booked a loss, which goes into the accruals line, so the loan EBITDA line, of about €450,000. This is weighing heavily on EL.En.'s division for laser sources. The other segment where we were counting on working is electric motors manufacturing. Since our customers are based in Europe, mainly in Europe, this market, as far as European demand is concerned, is quite struggling.

Andrea Cangioli

executive
#45

In addition, a few of our partners—our final partners—aren't in the greatest shape, since we manufacture and supply laser sources to makers of hairpin stripping systems and to electric motor manufacturing, which furnish devices to companies such as Magneti Marelli. As you're aware, Magneti Marelli, for example, at least within the United States, sought protection from creditors. I wanted to bring up this department, this small business unit, during my prepared remarks because, despite the weak financial results and revenue results this quarter, we're putting money into R&D, and we think these products could serve as the foundation for a revenue rebound in the coming quarters. Perhaps not in 2025—perhaps afterward—but I believe that even though some of our customers are enduring a difficult period, we hold a very compelling technology, and this technology will once more contribute accretively to our revenue and to our profitability.

Carlo Maritano

analyst
#46

I appreciate that.

Bianca Fersini-Mastelloni

executive
#47

There's another question coming in from Andrea Bonfà at Banca Akros. Andrea, go ahead.

Andrea Bonfà

analyst
#48

Good afternoon, everyone — Enrico, Andrea. Just a quick point on the duties matter. One thing that didn't come up is the fact that Brazil is now facing a 50% duty. As I recall, Brazil was meant to serve as one of the platforms for exporting industrial laser into the U.S. So if you could speak to that — whether it's actually a problem for you, or whether you're able to reroute that business out of Italy — that's basically my question for today. Thank you.

Andrea Cangioli

executive
#49

Thank you, Andrea. The sales we make into Brazil are to industrial manufacturers there who primarily produce goods for Brazil itself. Historically, in certain markets — plastic cutting, for instance — our Brazilian customers were shipping out their products, not the system; their cut products went to the United States for laser processing. Right now, as far as we're concerned, Brazil is a market that is, naturally, impacted by steep duties, though those duties apply to exporting into Brazil. We don't treat Brazil as a hub for shipments to any other destination. Incidentally, Brazil's performance was extraordinarily strong during this year's first six months. What I mean is, they posted record revenues totaling close to €10 million, which, considering how weak the real is, amounts to an all-time high in revenue when measured in Brazilian real. Even so, we remain upbeat about that market, and as of today we don't perceive any adverse impact coming from U.S. tariffs on the Brazilian market.

Andrea Bonfà

analyst
#50

If I could just follow up, I'd like to ask about the state of industrial laser exports to the U.S., given that, as far as I understand it, there isn't any local production there — is that right?

Andrea Cangioli

executive
#51

What I said in my remarks about the U.S. tariffs, I believe, also applies to how industrial laser systems are distributed. By the way, this is a very important week for us, because FabTech is taking place in Chicago this year and is going on right now. This is the week when our products are presented, especially for Kataj Penta, which has a very large stand this year. A big investment, and we hope for a big return. What I can say is that our offer is currently so diversified that I confirm no U.S. manufacturers are able to offer anything on the U.S. market close to what we are offering. In certain specific segments, fortunately, there are no competitors worldwide that can have the kind of offer we are offering in certain specific and smaller segments. So on the tariffs, the following applies. Because our distributors are applying interesting markups, they are able to handle the cost increase without affecting volumes and with only a marginal effect on their margin, and without asking us to reduce our margin further, given the fact that we are reducing our margin by 10% and more due to the weakening of the U.S.

Andrea Cangioli

executive
#52

On the dollar side itself — anyway, prior to FabTech kicking off, our outlook and our order backlog in the U.S. for sheet metal cutting were positive. At that point we felt optimistic. Next week, I'm expecting folks to return from that very important trade fair, and I want to see whether the perception of our market positioning — which is very positive in the United States — remains confirmed, with a high degree of differentiation. Again, as I said in my earlier remarks, so long as we're able to offer a differentiated product — and it has to be differentiated with high perceived value relative to U.S. manufacturers or other competitors worldwide — as long as we hold on to that perception of value, the 15% tariffs, which on laser cutting systems might be somewhat higher given that there's a little bit of steel in a little bit. Laser systems contain a lot of steel. Those 15% tariffs don't entirely alter the value chain of distribution in the United States. We can stay optimistic about the United States as an interesting market in which to sell our products.

Andrea Bonfà

analyst
#53

Last question, if I may. The amount of working capital you had at the close of last year mattered quite a bit. You're coming out of years in which sourcing material was, to put it mildly, difficult. Do you intend to bring that working capital, or the inventory, down in a structural way, or how are you thinking about it? Thanks.

Andrea Cangioli

executive
#54

In general, we sell products that carry relatively high margins, and we can never take the risk of being unable to deliver simply because we lack the materials available to manufacture high-margin products. For these reasons, we must plan ahead. Typically, the planning cycle peaks in working capital expansion during Q2, at the end of Q2 and Q3, since that is when we close the numbers for the end of the year, which also matches the quarter with the highest demand. We intend to improve our programming capabilities. We are putting investment into resources, into people, into software, but fundamentally, reducing the structural impact of working capital is not easy. When I say that overall working capital rose by €20 million across these first six months, and I don't regard that as a big issue, it's because I believe it will come down in the coming months and will stay more or less at the same levels. Whether we will manage to trim 1% or 2% or 3% in the impact of net working capital on sales, that we will need to see. We are establishing policies to try to reduce it, but we don't want to take the risk of running out of parts because we are trying to control inventory, since it wouldn't be worth it.

Andrea Cangioli

executive
#55

History teaches us this. I agree that net working capital sits at a fairly elevated level, but it helps to keep in mind that the majority of what we hold in stock won't decline in value as time passes, since none of it carries built-in obsolescence. Obsolescence comes only through innovation, and we work to manage innovation cycles so that we aren't sitting on older versions in inventory for long as we bring out new versions of our products.

Andrea Bonfà

analyst
#56

Thanks so much.

Andrea Cangioli

executive
#57

You’re welcome.

Bianca Fersini-Mastelloni

executive
#58

Our next question is from Emmanuel De Figueiredo at LBW Asset Management. Emmanuel, go ahead please.

Emmanuel de Figueiredo

analyst
#59

Good afternoon, and thanks. I’ve got just 2 questions. The first concerns the medical business, specifically U.S. tariffs. Could you briefly explain what your competitors are doing on pricing? Are they absorbing the tariff and taking the hit to their margins, or are they raising prices? What’s your view on that, and what are you doing? Second, still on medical, what would you call your best-performing product this year in medical? You said hair removal is weak, but which product is your best performer?

Andrea Cangioli

executive
#60

Thanks, Emmanuel. Appreciate the question. It's good to see you. Honestly, I don't know the specifics in any great detail. I haven't observed any price shifts in the U.S. market, so my assumption is that everyone is attempting to soak up the tariffs at some point along the chain. What I mean is, I'm not sure whether that happens at the origin. I'm not sure whether it happens at the distribution level, but as of today we aren't seeing any sudden changes in market pricing, even though the United States is dealing with inflation. On a year-over-year basis, prices are inflating. That leaves room to somehow absorb — not absorb, but pass back part of the tariffs to the end user without making a big difference in our approach relative to our other competitors. As for the successful products in medical, naturally the Magneto and the urology lasers are doing very well. In aesthetic, we have three products that are very successful. One of them is Onda Pro. Onda, as you remember very well, I'm sure, is our technology built on microwaves. Onda in Italian means wave, and originally it was a body contouring device. Onda Pro, its evolution that launched last year, adds a third hand piece used for the face, and so the system also becomes a skin rejuvenation device, with the ability to treat facial skin in order to tighten it.

Andrea Cangioli

executive
#61

It's an anti-aging device for tightening. The second very successful device is the Red Touch, which is an innovation that introduces a laser emitting in the red for rejuvenation on the face and on the décolleté. I leave the third, the most successful of our technologies, I touched this earlier in earlier conferences, is the CO2 laser. The CO2 laser, which is the first technology, the oldest technology that EL.En. has offered on the market, and the technology that we master and we improved in its effectiveness, starting from the technology base. Who visited our company knows that our facility has two kinds of technology for CO2 laser source: the glass technology, DC excited, the metal technologies are RF excited. The RF excited technology has come to such flexibility in the modulation of the beam, which allows extremely delicate tuning on the skin and is the winning technology on the U.S. market, by the way, particularly on the U.S. market for the rejuvenation application. Onda Pro, Red Touch, and Theta Pro are the game winners in this moment and are the units which, with increased sales in the U.S. and in Far East, are offsetting, at least partially offsetting, the decline in other disciplines.

Emmanuel de Figueiredo

analyst
#62

Thanks.

Bianca Fersini-Mastelloni

executive
#63

We've got Giovanni Salveti on the line with one more question for you, Andrea. Please go ahead, Giovanni.

Giovanni Selvetti

analyst
#64

That's my last question, I promise. No, I was mainly just curious about hair removal, because I've noticed there's been fairly solid growth in what you might call DIY laser hair removal devices — at least in the UK, you see them everywhere. I was wondering whether that's partly, in some way, eating into the market. If people can do this themselves rather than going to, say, a dedicated clinic, then demand just shifts from one side to the other, right? I was wondering whether that's something you're seeing, or whether you believe it's a genuine concern going forward.

Andrea Cangioli

executive
#65

I don't mean to sound shallow here, but those at-home devices that say they get rid of hair, or claim to, simply can't do the job on their own—for a straightforward physical reason: they don't put out enough energy to actually eliminate the hair. After a professional treatment, they might serve as maintenance. Put that way, they could reduce how many times you go to a professional location. Broadly, given today's available technologies, I don't believe they're effective enough to take market share away from our professional market. What I see is more competition arriving from lower-cost makers that have boosted performance, and that is consuming the low-level competition and pushing us to fight over a portion of the market that remains large—the high end—though it is smaller than the entire market. To remain effectively in this market, we must keep differentiating and keep enhancing performance. In recent years, performance has improved dramatically in terms of both financial ROI and, as a result, how effective laser systems are for hair removal. For our part, our pipeline holds additional technology improvements designed to raise effectiveness and ROI for our customers.

Andrea Cangioli

executive
#66

Honestly, I don’t believe those handheld devices meant for home use are having any impact on our market. Giovanni, I’ll look into this situation more thoroughly, and perhaps when we meet again at some point, I can come back to you with an answer that’s more, let’s say, informed.

Giovanni Selvetti

analyst
#67

Appreciate it.

Bianca Fersini-Mastelloni

executive
#68

All right, we’ve just gotten another question coming in from François Berthine. Please go ahead, François. François?

Speaker

unknown
#69

Yes, I did see his question. Sorry it took a moment to get the microphone connected. One question regarding the competition, particularly in the aesthetic sector, coming from Korea or from Israel: how is that relative competition developing?

Andrea Cangioli

executive
#70

Yeah. In the aesthetic market, Israeli and Korean firms are at the forefront of our competition, with plenty of companies—companies that have been around a long time and companies now bringing new products to market. Naturally, Israel brings Lumenis to mind, the long-standing, longest, oldest competitor out there, plus Syneron and also Sisram/Alma Laser. All of them compete with us. We don't believe we've lost any competitive edge against them over recent years. There's InMode, the leader by market cap, which in fact doesn't compete with us directly, since they sell RF technology with heavy marketing content and the use of testimonials. They're performing quite well, but we no longer sense a direct threat from them. A new company was just launched by Mr. Shimon Eckhouse, the former founder of both Lumenis and Syneron Candela. That company is called SoftWave. It's quite small. It also competes in rejuvenation and skin tightening devices. That covers Israel. As for Korea, the longest-lived company is Lutronic, which is now merged with Cynosure.

Andrea Cangioli

executive
#71

Their competition hits us hard, and the first reason is that the merger cost us Cynosure as a customer. That company used to buy a technology from us. Once they merged with a business holding more or less the same technology, naturally they will source that technology from Lutronic. Lutronic has been quite formidable in particular European markets. In France, for example, they hold the leading position. We sit in second place. Their technology development is extremely strong. As a competitor, they operate at a high level. Lutronic cannot be treated the way we can treat several other rivals coming out of Paris that still ship products well below par when it comes to reliability, technical specification, and overall product specification and quality. A second pair is now thriving in Korea. That company is Classys. It is a listed company. You can observe how, with revenue on the order of magnitude of $100 million per year today, if I'm not mistaken, they carry a market cap that is outstanding, above $2 billion. That reflects the rapid growth they forecast and the very high margin. In essence, Classys is replicating the InMode business model on a Korean basis, or at least their ambition is to replicate it.

Andrea Cangioli

executive
#72

Their device is sold at premium pricing despite being quite inexpensive, and right now they're doing very well. Once more, as we review all of these players, the rivals out of Israel strike us as a bigger threat—those competing with the same technological foundation we use, with InMode being the exception—compared with firms coming from the Far East, where product quality keeps getting better yet remains behind what Europe offers and what the Israeli and the West Korean company can deliver today.

Bianca Fersini-Mastelloni

executive
#73

Alright. At this point, our list shows no further questions registered. If investors have any additional questions on their side, I'd ask them to remain connected. There are no more questions. Okay. Ladies and gentlemen, that brings this conference to a close. Should you have anything you need to look into going forward, please feel free to reach out to Enrico Romagnoli, who will gladly respond to your inquiries. Thank you, everyone, for joining this conference, and we look forward to having all of you with us again next time. Goodbye, everybody. Bye.

Andrea Cangioli

executive
#74

Thanks.

Bianca Fersini-Mastelloni

executive
#75

Bye.

Nicola Fiore

unknown
#76

Thanks a lot. Goodbye.

Enrico Romagnoli

executive
#77

Take care.

Speaker

unknown
#78

That's all from us. The recording is now stopped.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete EL.En. S.p.A. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to EL.En. S.p.A. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in EL.En. S.p.A. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.